University Health Network, Toronto, Ontario, Canada.
University of Toronto, Toronto, Ontario, Canada.
Transfusion. 2019 Jun;59(6):1997-2006. doi: 10.1111/trf.15270. Epub 2019 Mar 28.
Transfusion-associated circulatory overload (TACO) is a leading cause of transfusion-attributable morbidity. It is unclear whether diuretics are safe and effective in preventing this reaction.
In a pilot controlled feasibility trial, inpatients 65 years or older ordered a single unit of red blood cells were randomized to pre-transfusion furosemide 20 mg or placebo intravenously. Primary outcome was the ability to enroll 80 patients within a 2-month time period. Secondary feasibility outcomes included proportion of RBC transfusions meeting eligibility criteria, proportion of eligible patients enrolled, and compliance to study protocol. Clinical outcomes included the incidence of TACO and associated complications.
Nine months of enrollment were required for 80 patients to complete the study, due primarily to fewer transfusions than expected meeting eligibility criteria and lower than anticipated consent rates. Protocol compliance was below target due to missing chart documentation of patient fluid balance, and transfusion infusion time. Blinding was maintained throughout the study and treatment arms were well-balanced. A single case of TACO occurred in each arm, for an overall incidence of 2.5%. No differences in peri-transfusion vital signs, B-natriuretic peptide, or signs of furosemide toxicity were observed.
The study protocol was not feasible as designed, primarily due to challenges in patient enrollment. Modifications to trial design to improve feasibility in future studies have been identified.
输血相关循环超负荷(TACO)是输血相关发病率的主要原因。目前尚不清楚利尿剂在预防这种反应方面是否安全有效。
在一项先导性、对照、可行性试验中,将 65 岁或以上的住院患者随机分为输血前静脉注射呋塞米 20mg 或安慰剂组,每组接受单单位红细胞输注。主要结局是在 2 个月的时间内招募 80 名患者。次要可行性结局包括符合入选标准的 RBC 输注比例、符合入选标准的患者比例以及对研究方案的依从性。临床结局包括 TACO 的发生率和相关并发症。
由于符合入选标准的输血比例低于预期,以及预计的同意率较低,因此需要 9 个月的招募时间才能完成 80 名患者的研究。由于患者液体平衡和输血输注时间的图表记录缺失,方案依从性低于目标。整个研究过程中保持了盲法,治疗组之间平衡良好。每个治疗组均发生 1 例 TACO,总发生率为 2.5%。在围输血生命体征、B 型利钠肽或呋塞米毒性迹象方面未观察到差异。
研究方案按照设计不可行,主要是由于患者入组方面的挑战。已经确定了改进未来研究可行性的试验设计修改。